About Us

Prescient is a product strategy and decision support consultancy that helps clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients, customers and shareholders. Founded in London in 2007, Prescient has since expanded its global reach through offices in New York, San Francisco, New Delhi and Beijing. Prescient partners with most of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech organizations.

Our work is truly global, with about 65% of our engagements being focused on the mature markets of North America, Europe and Japan, and the remaining 35% helping clients realize opportunities in the emerging markets of APAC, LATAM and EMEA. Besides supporting innovative products in oncology, immunology, cardiology, neurosciences and infectious diseases, we are heavily involved in biosimilars, generics, vaccines and rare diseases.

Prescient Overview

Partnering With Us

Our engagements are designed to answer three fundamental questions asked by clients:

  • How will the market and competition look at a specific time in the future, and what must we demonstrate to succeed?
  • How can we develop a clinical and commercial value proposition that resonates with future market needs and stands out from the competition?
  • Which customers will determine the success of our brand and how can we communicate our value to them?

Our relationships with assets, brands or franchises typically last for more than 5 years. We often start a partnership with a product team in early Phase II and provide constant support through launch and beyond.

Our success is built on employing the best people and developing a culture where we can guarantee our clients quality, flexibility and humility.

Over the past decade, we have seen our clients’ businesses evolve from a predominantly primary care model to more targeted, patient-centric specialty businesses. Prescient has joined them on this journey, building an integrated team of more than 100 functional, therapeutic and methodology experts.

Prescient Healthcare Group

Corporate Brochure

Download Prescient's Corporate Brochure.
Functons with which Prescient partners with the clients.

Meet Our Leadership

Dr. Nick Edwards

Chairman

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgery before joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Jamie Denison-Pender

CEO

Jamie is our CEO and a career consultant, having spent more than 20 years growing and managing healthcare-focused consultancies. In 2007, he became managing director of a global competitive strategy consultancy and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010 and led a management buyout in 2014. Jamie remains actively involved with our clients, mainly focusing on strategic simulation workshops and mature brand strategies.

Dr. Rakesh Verma

President (EMEA and APAC)

Rakesh is the President of our EMEA and APAC businesses. After earning a degree in veterinary medicine, he completed his Master’s and doctoral degrees in immunology at Imperial College, School of Medicine, London. He was then recruited by oncology biotech firm Antisoma, which specialized in the development and out-licensing of monoclonal antibodies. He joined Prescient in 2007. His renowned expertise in the development and commercialization of biologics makes him an extremely valuable asset to our oncology, immunology and biosimilar clients.

Dr. Mark Little

President (North America)

Based out of our New York office, Mark is the President of our North American business. After completing a PhD in biochemistry at The Ohio State University, he spent more than 10 years running GSK’s competitive strategy function and 10 years as a key member of Covance’s executive strategy team. Mark engaged with Prescient throughout his tenure with GSK and Covance before joining us in 2013. His industry knowledge, built from both big pharma and CRO perspectives, enables Mark to quickly and effectively identify the opportunities and challenges that clients face, and translate them into solutions.

Andrew McMeeking

CFO

Andrew joined our team in 2012 after holding finance director positions in marketing services companies such as Publicis and Gyro. He is a qualified chartered accountant and holds an honors degree in accountancy from Dundee University. He manages Prescient’s finances and is the company secretary. He was heavily involved in setting up the shared resources service center in the UK and arranging Prescient’s de-merger/MBO in 2014.

Nick Denison-Pender

COO

Nick, our COO, joined Prescient in 2010. After studying engineering, he held various positions focused on business improvement, mainly in the construction industry. He has worked in many parts of the world, establishing and embedding businesses into local markets. At Prescient, he holds overall responsibility for our operations and infrastructure and has been instrumental in setting up the departments, processes and procedures required to support a growing business.

John DiGiovanni

Baird Capital Investor

John sits on our board of directors. He holds a BA from the Eli Broad College of Business at Michigan State University, where he graduated with honors, an MPA from Harvard University’s Kennedy School of Government and an MBA from Northwestern University’s Kellogg School of Management. John worked in investment banking at Bank of America Merrill Lynch, focusing on mergers and acquisitions, restructurings, and equity and debt offerings before joining Baird Capital in 2007. He serves on the board of Baird Capital portfolio company Myelin Communications, is on the Auxiliary Board at the Chicago Children’s Museum and has served as an Education Pioneers Fellow.

Andrew Ferguson

Baird Capital Investor

Andrew, one of our non-executive board members, has close to 25 years’ experience in the private equity industry. He started his professional career at Price Waterhouse in 1986, where he qualified as a chartered accountant before moving into a corporate finance role. He joined North of England Ventures in 1993 to manage a regional investment fund before moving to Granville, subsequently Baird Capital Partners, in 1996. At Baird, he is responsible for investment activities in the UK with a particular focus on the business services and healthcare sectors and has held directorships in a large range of companies across these sectors.

Nader Naeymi-Rad

Advisor

Nader serves on Prescient’s Board as a Non-Executive Director. He has a BA from Georgetown University. He was previously the Chief Executive Officer of Campbell Alliance, where he oversaw all of the firm’s business units to ensure its continued growth, commitment to client service, development of new service lines and geographic expansion. Nader is an expert in developing and implementing business strategy, process improvement and business development solutions for clients in the pharmaceutical and biotechnology industries.

Dr. Arvind Raghunath

Vice President

Arvind has been a valuable member of the Prescient team since 2010. He holds a medical degree and a PhD. He started his career as a research scientist at the International Centre for Neurotherapeutics in Dublin, where he focused on targeting and developing novel biopharmaceuticals for neurological conditions. He then moved to Vimta Labs, a leading Indian CRO, where he developed and tested biosimilars. Since joining Prescient, Arvind has developed a unique understanding of the ever-evolving scientific, regulatory, clinical and market access environments.

Michael Sale

Vice President

Michael is our Head of Commercial Planning. A pharmacist by training, he started his career on the industry side with Eli Lilly as a business unit manager for its Brazilian affiliate before moving to the global organization. He later joined Eisai as Director of Global Neuroscience Marketing, and then Abbott (now AbbVie), where he was Head of Commercial Strategy for a portfolio of specialty products. During his time at AbbVie, Michael worked closely with Prescient for several years. His experience in developing and implementing specialty brand strategies across the Americas, Europe and Asia adds huge value for our clients.

Dr. Anthony Starling

Vice President

Anthony is one of the longest-serving members of our team, having joined in 2002. He earned his PhD in pharmacology before becoming a postdoctoral researcher at the University of Southampton. From there, he joined the world of healthcare market research, working for the likes of MMR International, IMS Health and NOP World (now GfK). He has consulted across the therapeutic spectrum and throughout the product life cycle but particularly enjoys developing clinical strategies within oncology, infectious disease and cardio-metabolic diseases.

Dr. Joanne Taylor

Vice President

Joanne, who has a PhD in developmental neuroscience from King’s College London, heads up our neuroscience business. After completing a postdoctoral fellowship, she joined Eisai. Over her 18-year career there, she led global teams in the discovery of novel therapeutic strategies for neurological conditions, in particular Alzheimer’s disease, multiple sclerosis and Parkinson’s disease. As Director of Strategic Research Planning, she led reviews of Eisai’s neuroscience portfolio to identify areas of major focus and investment. Since joining Prescient in 2011, Joanne has supported portfolio, clinical and regulatory strategies for a wide array of clients.

Swati Anand

Swati manages our New Delhi office and is responsible for Prescient’s APAC business. Swati has an MSc in biotechnology and pharmacology, and an MBA from the University of Sheffield. After joining us in London in 2008, she moved to India in 2010 to open our New Delhi office, which she has built into a critical part of our business. During her time with Prescient, she has consulted across a wide range of therapy areas and been actively involved in client engagements. In the past four years, she has specialized in mature brand planning and launching specialty products in the APAC region.

Harminder Bhatia

Harminder has been delivering high-impact projects to our clients since 2010. He has an MS degree in chemistry from Virginia Commonwealth University and a BPharm degree from Panjab University, Chandigarh, India. He is also a registered pharmacist in India. Before joining Prescient, he was a senior analyst with Evalueserve and a regulatory affairs executive with Promed Research Centre. Harminder now focuses on analyzing competitors and market scenarios for biosimilar, generic and novel products. He is well versed in both oncology and immunology biologic products, especially those likely to face biosimilar or generic competition.

Courtney Carlson

Courtney, our Associate Director of QC and Compliance, joined Prescient in 2012. After earning a master’s degree in Spanish translation, she pursued a job opportunity in Bogotá, Colombia, where she translated medical, legal and technical texts and designed an assessment program to monitor the quality of her fellow translators’ work. Courtney now uses her attention to detail to oversee Prescient’s experienced QC Team, which is responsible for editing all of our deliverables, and to ensure that Prescient has the necessary resources in place to fulfill our legal and contractual obligations.

Ben Doran

Ben manages our New York office and is responsible for our East Coast and Midwest business. He holds a BSc in biomedical sciences and an MSc in biomedical engineering, and gained eight years’ experience in biotech prior to joining Prescient in 2010. Ben has held progressively more senior roles at Prescient, which has given him a deep understanding of what is needed to build and motivate teams that deliver results with a high degree of client satisfaction. Ben has also been closely involved in managing projects across multiple therapeutic areas, including oncology, immunology and biosimilars.

Nadia Gonzalez

Nadia joined the Prescient team as the US Financial Controller and HR Director. After earning her accounting degree, she developed financial expertise through working with high-end retail and luxury brands headquartered in New York City. While working in retail, Nadia was responsible for the financial reporting and oversight of nationally recognized brands with a presence across the country. The technical expertise and business acumen that she has acquired over the past 15 years have proven to be an invaluable asset to our organization.

Pip Keys

Pip is our Director of European Stakeholder Insights and is responsible for designing, implementing and delivering research solutions for clients in pharmaceutical and biotechnological companies. She holds a BSc First-Class Honors in psychology and health science from the University of the West of England and an MSc in ergonomics from Birmingham University. Her experience in healthcare market research spans more than 20 years. She has supported global product launches in mature and growth markets and implemented research initiatives throughout the product life cycle. An expert qualitative researcher with sound quantitative skills, Pip has a particular interest in understanding the psychology that influences beliefs and behavior in the context of market research.

Dr. Aviral Maheshwari

Aviral has been a key member of the Prescient team since 2010. He completed his MBBS and MS degrees at Jawaharlal Nehru Medical College, India, and his MBA at IESE Business School, Spain. He practiced as a trauma surgeon for nearly eight years, and then assumed strategic consultancy roles with GlaxoSmithKline Biologicals in Belgium and Grail Research, a subsidiary of Integreon Group. At Prescient, Aviral has worked on a variety of projects across different therapeutic areas, examining all aspects of the product life cycle from R&D strategy and clinical development, to pre-launch and launch activities, sales and marketing activities, and life cycle management strategies. Aviral has become an expert on the manufacturing and supply chain as well as market access strategies across both developed and emerging markets.

Christina Maffei

Christina joined Prescient as our Principal, Global Marketing, and leads all marketing and communications functions. After earning a master’s degree in pharmaceutical business, she pursued careers in both non-profit and commercial sectors. Her experience includes leading marketing strategy for global oncology teams, as well as regionally for the Americas and in emerging markets. Christina is responsible for elevating the positioning and messaging of the Prescient brand through the development of strategic marketing programs and thought leadership initiatives.

Dr. Michelle Miranda

Michelle has risen through the ranks of Prescient, from a Senior Analyst to her current role as a Principal. She has a PhD in molecular oncology and an MBA in pharmaceutical management and marketing. Michelle has several years of pharmaceutical experience both in consulting and the industry. She served as Senior Manager of Strategic Planning at Wockhardt USA, reporting directly to the president of the company. There, she was responsible for entry strategies into emerging markets for Wockhardt’s generic and biosimilar products. At Prescient, Michelle’s projects focus on oncology (solid and hematological tumors), rheumatology and immunology.

Dr. Wilfredo Ortiz

Wilfredo has been a trusted member of our team since 2009. He has a PhD from the University of Florida in computational chemistry with a focus on molecular simulations of polymers and biomolecules. He also completed a two-year postdoctoral fellowship at the University of Houston as part of the NIH Nanobiology Training Program, performing theoretical research on DNA microarrays. During his doctoral studies, he won awards for excellence in teaching, graduate research and scientific publication. Since joining Prescient, Wilfredo has specialized in vaccines, cardiology and metabolic diseases, respiratory disease and biosimilars.

Dr. Kallal Pramanik

Kallal is one of the longest-serving members of our India-based team. He has master’s and doctoral degrees in biotechnology, as well as a master’s degree in business administration. After holding various academic research posts in oncology, Kallal became a Lead Scientist at Connexios Life Sciences, where the focus of his group was to design in vitro and ex vivo assays reflecting human pathologies in type 2 diabetes mellitus and to test the efficacy of in-house drugs. Since joining Prescient in 2010, Kallal has managed new product and mature product brand planning projects in the areas of neurology, oncology, immunology and diabetes in both regulated and semi-regulated markets.

Dr. Elisavet Primpidou

Elisavet joined Prescient in 2008 and heads up our business development activities in Europe. She holds a PhD in molecular immunology from Brunel University, and an MSc in medical genetics and a BSc in biology from the Royal Holloway University of London. As a consultant to the pharmaceutical industry, Elisavet has gained extensive experience in various aspects of drug development and commercialization, strategic marketing and life cycle management, providing critical analysis and recommendations to brand teams supporting new and existing products in oncology, hematology, neuroscience and other areas. Elisavet uses her expertise in evidence gathering to identify key unmet needs, gaps in strategy, opportunities for differentiation and potential threats.

Dr. Fancy Sarswat

Fancy joined Prescient in 2010 and is one of our Principals. She received her Bachelor’s degree in pharmaceutical sciences from Goa College of Pharmacy, India, and her PhD in pharmaceutical sciences from Texas Tech University Health Sciences Center, Amarillo, Texas. She worked as an assistant professor in the College of Pharmacy at Lipscomb University, Nashville, Tennessee, where she taught the biopharmaceutics, pharmacokinetics and pharmaceutics courses and published research in highly distinguished international peer-reviewed journals. Besides her experience in academia, Fancy has worked at Abbott Laboratories Limited and Ranbaxy Laboratories in both the production and the quality control departments. At Prescient, Fancy has managed respiratory and vaccine projects and worked extensively in the neuroscience space, especially on neurodegenerative and neurodevelopmental disorders. Furthermore, Fancy has extensive experience supporting pharma clients both defending from biosimilars and developing biosimilars of their own.

Dr. Neil Sheehy

Neil has been a linchpin of our West Coast operations since 2012. He completed his PhD in developmental biology at the University of California, San Francisco (UCSF). In 2011, he worked as a member of a consulting organization at UCSF that advised biotechnology start-ups founded on intellectual property invented in university laboratories. Neil also worked as an analyst intern at Kearny Venture Partners, where his responsibilities included helping model recent trends in biotechnology acquisitions and assessing the technical merits of potential investments. At Prescient, Neil has managed projects across multiple therapeutic areas, including inflammatory disease, respiratory disease and especially oncology.